News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
622,771 Results
Type
Article (44525)
Company Profile (344)
Press Release (577892)
Multimedia
Podcasts (114)
Webinars (18)
Section
Business (168576)
Career Advice (2469)
Deals (30522)
Drug Delivery (121)
Drug Development (79239)
Employer Resources (148)
FDA (14719)
Job Trends (13093)
News (297937)
Policy (28777)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2699)
Academic (1)
Accelerated approval (37)
Adcomms (31)
Allergies (151)
Alliances (43138)
ALS (187)
Alzheimer's disease (1759)
Antibody-drug conjugate (ADC) (353)
Approvals (14951)
Artificial intelligence (549)
Autoimmune disease (168)
Automation (39)
Bankruptcy (327)
Best Places to Work (10684)
BIOSECURE Act (17)
Biosimilars (184)
Biotechnology (258)
Bladder cancer (167)
Brain cancer (62)
Breast cancer (655)
Cancer (5023)
Cardiovascular disease (430)
Career advice (2096)
Career pathing (39)
CAR-T (298)
CDC (50)
Cell therapy (794)
Cervical cancer (32)
Clinical research (67728)
Collaboration (1772)
Company closure (4)
Compensation (875)
Complete response letters (71)
COVID-19 (2696)
CRISPR (105)
C-suite (929)
Cystic fibrosis (148)
Data (6447)
Decentralized trials (2)
Denatured (25)
Depression (151)
Diabetes (509)
Diagnostics (6190)
Digital health (40)
Diversity (8)
Diversity, equity & inclusion (41)
Drug discovery (274)
Drug pricing (187)
Drug shortages (25)
Duchenne muscular dystrophy (252)
Earnings (65399)
Editorial (60)
Employer branding (20)
Employer resources (140)
Events (94899)
Executive appointments (1031)
FDA (17829)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1475)
Gene editing (221)
Generative AI (48)
Gene therapy (666)
GLP-1 (1025)
Government (4527)
Grass and pollen (7)
Guidances (381)
Healthcare (17332)
HIV (68)
Huntington's disease (51)
IgA nephropathy (88)
Immunology and inflammation (285)
Immuno-oncology (69)
Indications (124)
Infectious disease (2983)
Inflammatory bowel disease (210)
Inflation Reduction Act (16)
Influenza (122)
Intellectual property (258)
Interviews (528)
IPO (14393)
IRA (53)
Job creations (2769)
Job search strategy (1689)
JPM (66)
Kidney cancer (20)
Labor market (65)
Layoffs (553)
Leadership (41)
Legal (6117)
Liver cancer (94)
Longevity (16)
Lung cancer (694)
Lymphoma (379)
Machine learning (43)
Management (52)
Manufacturing (775)
MASH (181)
Medical device (11486)
Medtech (11535)
Mergers & acquisitions (17167)
Metabolic disorders (1339)
mRNA (176)
Multiple sclerosis (166)
NASH (23)
Neurodegenerative disease (356)
Neuropsychiatric disorders (102)
Neuroscience (3098)
Neurotech (1)
NextGen: Class of 2026 (5990)
Non-profit (4158)
Now hiring (64)
Obesity (631)
Opinion (299)
Ovarian cancer (168)
Pain (211)
Pancreatic cancer (240)
Parkinson's disease (305)
Partnered (32)
Patents (508)
Patient recruitment (519)
Peanut (61)
People (56035)
Pharmaceutical (52)
Pharmacy benefit managers (22)
Phase 1 (21283)
Phase 2 (29887)
Phase 3 (22255)
Pipeline (5695)
Policy (298)
Postmarket research (2393)
Preclinical (8986)
Press Release (60)
Prostate cancer (256)
Psychedelics (56)
Radiopharmaceuticals (300)
Rare diseases (943)
Real estate (4550)
Recruiting (64)
Regulatory (22680)
Reports (31)
Research institute (2349)
Resumes & cover letters (363)
Rett syndrome (30)
RNA editing (21)
RSV (75)
Schizophrenia (161)
Series A (249)
Series B (195)
Service/supplier (3)
Sickle cell disease (106)
Special edition (23)
Spinal muscular atrophy (164)
Sponsored (38)
Startups (3232)
State (2)
Stomach cancer (19)
Supply chain (97)
Tariffs (75)
The Weekly (88)
Vaccines (1006)
Venture capital (95)
Weight loss (419)
Women's health (82)
Worklife (19)
Date
Last 7 days (815)
Last 30 days (2464)
Last 365 days (28715)
2026 (4604)
2025 (29096)
2024 (33626)
2023 (37497)
2022 (48413)
2021 (52024)
2020 (50008)
2019 (42544)
2018 (32071)
2017 (29660)
2016 (28191)
2015 (32973)
2014 (25388)
2013 (20574)
2012 (21779)
2011 (22687)
2010 (20427)
Location
Africa (758)
Alabama (87)
Alaska (4)
Arizona (242)
Arkansas (13)
Asia (37886)
Australia (7477)
California (10730)
Canada (3245)
China (1129)
Colorado (443)
Connecticut (429)
Delaware (340)
Europe (85349)
Florida (1632)
Georgia (332)
Hawaii (3)
Idaho (59)
Illinois (813)
India (68)
Indiana (474)
Iowa (18)
Japan (435)
Kansas (118)
Kentucky (36)
Louisiana (26)
Maine (60)
Maryland (1341)
Massachusetts (7812)
Michigan (305)
Minnesota (565)
Mississippi (6)
Missouri (126)
Montana (28)
Nebraska (25)
Nevada (112)
New Hampshire (79)
New Jersey (2974)
New Mexico (26)
New York (2842)
North Carolina (1400)
North Dakota (7)
Northern California (5166)
Ohio (302)
Oklahoma (16)
Oregon (39)
Pennsylvania (2144)
Puerto Rico (23)
Rhode Island (43)
South America (1026)
South Carolina (63)
South Dakota (1)
Southern California (4294)
Tennessee (157)
Texas (1684)
United States (38230)
Utah (338)
Vermont (1)
Virginia (245)
Washington D.C. (71)
Washington State (889)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
622,771 Results for "calliditas therapeutics formerly known as pharmalink".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Calliditas Therapeutics to Present at the American Society of Nephrology Kidney Week
November 5, 2025
·
8 min read
Press Releases
Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome at the American Society of Nephrology Kidney Week
November 10, 2025
·
3 min read
Press Releases
Calliditas Therapeutics Presented at the 62nd European Renal Association Congress
June 10, 2025
·
3 min read
Calliditas Therapeutics to Attend Conferences in April
Calliditas Therapeutics AB today announced that its management will be attending the following upcoming investor and industry conferences.
April 9, 2024
·
1 min read
Press Releases
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
December 23, 2025
·
9 min read
Deals
Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company
Asahi Kasei Corp. announces that it will offer the shareholders of Calliditas Therapeutics AB to acquire the shares of the pharmaceutical company Calliditas for the purpose of making Calliditas a wholly-owned subsidiary of Asahi Kasei through a voluntary tender offer for Calliditas.
May 28, 2024
·
7 min read
Press Releases
BreezeBio (Formerly GenEdit) Announces Series B Financing to Advance Internal Pipeline of Precision Genetic Medicines
February 25, 2026
·
4 min read
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
Calliditas Therapeutics AB today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO ® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN).
May 28, 2024
·
8 min read
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
Calliditas Therapeutics AB today announced upcoming data presentations and a sponsored symposium at the 61st European Renal Association (ERA) Congress, in Stockholm, Sweden on May 23 - 26, 2024.
May 15, 2024
·
6 min read
Deals
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
The Board of Directors of Calliditas Therapeutics AB unanimously recommends that the shareholders and holders of American Depositary Shares of Calliditas Therapeutics AB accept the public tender offer by Asahi Kasei Corporation.
May 28, 2024
·
24 min read
1 of 62,278
Next
